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Abstract
Background: Copeptin, part of the vasopressin precur-
sor, is increasingly used as marker for vasopressin and is 
claimed to have better ex vivo stability. However, no study 
has directly compared the ex vivo stability of copeptin and 
vasopressin.
Methods: Blood of ten healthy volunteers was collected in 
EDTA tubes. Next, we studied the effect of various pre-ana-
lytical conditions on measured vasopressin and copeptin 
levels: centrifugation speed, short-term storage tempera-
ture and differences between whole blood and plasma, 
long-term storage temperature and repeated freezing and 
thawing. The acceptable change limit (ACL), indicating 
the maximal percentage change that can be explained by 
assay variability, was used as cut-off to determine changes 
in vasopressin and copeptin.
Results: The ACL was 25% for vasopressin and 19% for 
copeptin. Higher centrifugation speed resulted in lower 
vasopressin levels, whereas copeptin concentration was 
unaffected. In whole blood, vasopressin was stable up to 
2  h at 25 °C and 6  h at 4 °C. In plasma, vasopressin was 
stable up to 6 h at 25 °C and 24 h at 4 °C. In contrast, copep-
tin was stable in whole blood and plasma for at least 24h 
at both temperatures. At – 20 °C, vasopressin was stable 
up to 1 month and copeptin for at least 4 months. Both 
vasopressin and copeptin were stable after 4 months when 
stored at – 80 °C and – 150 °C. Vasopressin concentration 
decreased after four freeze-thaw cycles, whereas copeptin 
concentration was unaffected.
Conclusion: Vasopressin levels were considerably affected 
by pre-analytical conditions, while copeptin levels were 
stable. Therefore, a strict sample handling protocol for 
measurement of vasopressin is recommended.
Keywords: copeptin; ex vivo; stability; vasopressin.
Introduction
In clinical and epidemiological studies copeptin is 
increasingly used as a marker for vasopressin, an impor-
tant hormone for water homeostasis [1]. Copeptin, a 
39-aminoacid glycopeptide, is part of the vasopressin pre-
cursor hormone pre-pro-vasopressin. When this precursor 
is split, copeptin and vasopressin are produced in equi-
molar amounts [2]. It has been demonstrated that copep-
tin levels correlate well with vasopressin levels during 
physiological changes in plasma osmolality, from water 
excess to dehydration, and also in pathologic states, for 
example, in septic shock [3–6]. Moreover, a promising 
role for copeptin as a diagnostic marker in the differentia-
tion of vasopressin-driven fluid homeostasis disorders as 
hyponatremia and polydipsia, and as prognostic marker 
in cardiovascular, kidney disease and critical illness, for 
example, pneumonia, has emerged in the literature [7, 8].
The rising popularity of copeptin as a surrogate 
marker for vasopressin is due to the laborious assay 
and presumed limited ex vivo stability of vasopressin in 
comparison with copeptin [2]. However, a review of the 
literature reveals that the effects of various relevant pre-
analytical conditions, such as centrifugation force and 
several short- and long-term storage conditions, on both 
vasopressin and especially copeptin have not been inves-
tigated (Table 1). The available evidence is sometimes 
contradictory and often outdated, as the method for vaso-
pressin measurement has changed considerably over the 
past decades and results obtained in the past with the 
older assays may therefore not be valid [11]. Moreover, no 
direct comparison of the ex vivo stability of vasopressin 
and copeptin has been made so far.
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Table 1: Overview of literature on ex vivo stability of vasopressin and copeptin.
  Vasopressin   Copeptin
Type of collection tube
 Plasma   In EDTA tubes more stable compared to serum tubes, 
no significant difference compared to heparin and 
fluoride tubes [9]
  In EDTA tubes more stable compared to 
serum, heparin, and citrate tubes after 14 
days, however, no difference initially [3, 10]
Centrifugation settings
 Plasma   Associated with platelet count and inversely 
associated with centrifugation speed [11, 12]
  Unknown
Storage at room temperature 
(up to 30 °C)
 Whole blood   ↑ after 2 h [11, 13]   = up to 72 h (although larger dispersion of 
data) [14]
 Plasma   ↓ after 4 ha [9]; = up to 5 h [12]; ≠ after 96 h [15]; ↓ 
after 12 ha [16]
  = up to 14 days (although larger dispersion 
of data) [3]
Storage at 4 °C
 Whole blood   = up to 24 h [13]; = up to 48 h [11]   Unknown
 Plasma   = up to 5 h [12]; ↓ after 2 daysa [15]; = up to 5 days [9]   = up to 14 days [3]
Freezer storage at – 20 °C
 Plasma   ↓ after 24 hb [17]   = up to 4 weeks [10]
Freezer storage at – 80 °C
 Plasma   = up to 1 montha [16]   Unknown
Freezer storage at – 150 °C
 Plasma   Unknown   Unknown
Freeze-thaw effect
 Plasma   = 3 cycles [17]; = 3 cyclesa [16]   = 4 cycles [3]
= Stable; ↑ increase; ↓ decrease; ≠ change of more than 10%, decrease or increase not stated; ameasured synthetic vasopressin added to 
human plasma. All samples were collected in EDTA tubes except the study indicated by b(heparin tubes).
This study aimed to investigate the effect of centrifuga-
tion speed, various short-term storing conditions pre- and 
post-centrifugation, long-term freezer storage, and repeated 
freeze-thaw cycles on both copeptin and vasopressin levels 
in blood and plasma to provide evidence based instructions 
for optimal pre-analytical sample handling.
Materials and methods
Study population and design
Ten healthy volunteers were included in this study in December 2015. 
The study was performed in accordance with the principles of the 
Declaration of Helsinki and was exempted from review by the Medi-
cal Ethical Committee of the University Medical Center Groningen. 
All participants gave written informed consent.
Blood sample collection was performed at 08:00 am after over-
night fasting. Blood samples were collected in ethylenediaminetet-
raacetic acid (EDTA) tubes. Collection in such tubes ensures the best 
stability of vasopressin and copeptin (Table 1). The tubes were placed 
on ice immediately after blood collection. Thereafter, several pre-
analytic sample handling procedures were evaluated.
To study the effect of relative centrifugal force (RCF), three EDTA 
tubes of every participant were centrifuged for 10 min at 4 °C at 800 g, 
at 2000 g and at 5000 g, respectively. Immediately after centrifugation, 
the platelet count, and plasma vasopressin and copeptin levels were 
determined. In all other experiments, plasma samples were obtained 
using an RCF of 2000 g for 10 min at 4 °C, which is routine in clinical 
practice. Second, the effect of short-term storage duration and storage 
temperature before measurement of vasopressin and copeptin was 
studied. Whole blood and plasma samples were stored at 25 °C and at 
4 °C for 2, 6 and 24 h. Immediately after these storage periods, whole 
blood samples were centrifuged at 2000 g and together with the plasma 
samples stored at – 80 °C until measurement of vasopressin and copep-
tin after 1 week. As a reference, a plasma sample was stored at – 80 °C 
for 1 week immediately after collection. Third, the effect of long-term 
storage and freezer temperature on plasma levels of vasopressin and 
copeptin was evaluated. For each patient, samples were stored at three 
different temperatures (– 20 °C, – 80 °C, and – 150 °C). These samples 
were measured after 1 week, 1 month, and 4 months. Finally, the effect 
of one, two and four freeze-thaw cycles on the plasma concentration of 
vasopressin and copeptin was studied. During each cycle, a sample was 
frozen to – 80 °C and thereafter thawed to room temperature. Gradual 
temperature change, from – 80 °C to room temperature and vice versa, 
was ensured in all samples by storing samples first at – 20 °C for 2 h 
before further processing. Samples that were stored at – 150 °C were 
transferred to – 80 °C for one night prior to thawing.
Laboratory analysis
Vasopressin and copeptin measurements were performed in the clin-
ical chemistry laboratory of the IJsselland Hospital, Capelle aan den 
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IJssel, The Netherlands. Vasopressin was measured with a competi-
tive radioimmunoassay using rabbit anti-vasopressin-antiserum and 
a radio-iodinated vasopressin [125I] tracer (DRG Diagnostics, Marbug, 
Germany). Documented cross-reactivity of the used antibody with 
oxytocin is < 0.1%. Solid phase extraction with acetic acid was per-
formed to separate vasopressin from plasma with use of C18 columns 
(Waters Chromatography BV, Etten-Leur, The Netherlands), which 
has been suggested to be superior to ethanol extraction [11]. In our 
study, a recovery of 91.9 ± 2.5% was found. The detection limit of the 
vasopressin assay is 0.25 pmol/L. Values below the detection limit 
were considered equal to 0.25 pmol/L in the analyses.
Copeptin was measured on a semi-automatic Kryptor analyzer 
(ThermoFisher, Henningsdorf/Berlin, Germany) using a sandwich 
chemiluminescent immunoassay (ThermoFisher). Two types of anti-
bodies, anti-copeptin sheep and anti-copeptin mouse antibodies 
with luminescent proteins attached, are added to the blood samples 
and form complexes with the copeptin molecules. Upon activation 
with a nitrogen laser, the antibody-copeptin complexes emits an 
elongated luminescent signal compared to the free antibodies, allow-
ing quantification of the copeptin concentration. The detection limit 
of the copeptin assay is 0.7 pmol/L. No values below this detection 
limit were found in this study.
Assay functionality of the vasopressin and copeptin assays was 
assessed by measuring high and low levels of the analytes in pooled 
plasma from human subjects in four-fold for five consecutive days 
according to the global Clinical and Laboratory Standards Institute 
(CLSI) EP15 protocol. In this way, the intra-assay and total coefficient 
of variation (CV) were determined. The intra-assay, or within-day CV 
was calculated by dividing the mean within-day standard deviation (SD 
within) by the grand mean of all measured values, times 100%. The total 
CV is derived from the SD of both within- and between day assay vari-
ation, which is calculated by using the formula: SD total = √ ((3/4) × SD 
within × SD within + B) [18]. B denotes the between-day variation, by 
averaging the differences between day means and the grand mean. The 
total SD was thereafter also divided by the grand mean, times 100%.
Data analysis
All variables are presented as median and interquartile range (IQR) 
because of our small sample size and skewed data distribution. For 
each participant separately, the percentage change in analyte con-
centration was calculated as Tsc/Tr × 100 with Tr and Tsc represent-
ing the reference concentration and concentration of that study 
condition, respectively. These calculated changes were evaluated 
for presence of outliers, using Grubbs analysis [19, 20]. Outliers were 
excluded from analysis (Supplemental Data, Table 1) and the mean 
percentage differences without outliers were compared with the 
acceptable change limit (ACL). The ACL is the maximal percentage 
change that can be explained by assay variability, calculated with 
the following formula: ACL = Z √2 × CVa, with a Z-value of 1.96 thus 
representing a 95% confidence range [21]. The analytical coefficient 
of variation (CVa) was obtained by dividing the SD of the data from 
the assay functionality assessment in the lower range of hormone 
concentration by the median of the hormone concentrations meas-
ured directly after centrifugation at 2000 g. The ACL is considered our 
primary outcome analysis. Friedman’s ANOVA tests were performed 
as secondary analysis, with a post-hoc analysis of differences using 
Wilcoxon signed-rank tests, with Bonferroni corrections to correct 
for multiple testing. Correlations between vasopressin and copeptin 
concentrations were assessed using Spearman’s correlation analy-
sis. p-Values of < 0.05 were considered statistically significant. All 
analyses were performed using SPSS (IBM Statistics version 22.0) and 
Graphpad Prism (version 5.0).
Results
Definition of change
The intra-assay CV of vasopressin was determined as 10.8% 
at 1.2 ± 0.1 pmol/L (low range) and 5.5% at 5.4 ± 0.3 pmol/L 
(high range). The total CV of vasopressin was 11% and 4.8% 
for the low and high range, respectively. The intra-assay 
CV of copeptin was 9.0% at 3.0 ± 0.3 pmol/L (low range) 
and 2.2% at 28.9 ± 0.6 pmol/L (high range). The total CV of 
copeptin was 13.1% and 2.2% for the low and high range, 
respectively. The median vasopressin and copeptin values 
of samples centrifuged at 2000 g were 1.46 pmol/L and 5.73 
pmol/L, respectively (Table 2). For the calculation of the 
ACL, analytical CVs were estimated at 9.1% for vasopres-
sin and 6.9% for copeptin. This resulted in an ACL of 25% 
for vasopressin and of 19% for copeptin. A mean percent-
age changes in hormone concentration during the various 
pre-analytical sample handling procedures was defined as 
significant in case this change exceeded these ACL values.
Effect of centrifugation speed
As shown in Table 2, the plasma platelet count gradually 
decreased when whole blood was centrifuged at higher 
RCF (p < 0.001). Plasma vasopressin concentration also 
decreased significantly at higher centrifugation speed, 
with respectively 73% and 86% when these whole blood 
samples were centrifuged at 2000 g and 5000 g compared 
to 800 g, thus exceeding the ACL. In contrast, plasma 
copeptin levels did not differ across samples obtained 
with these three centrifugation speeds (Table 2). Plasma 
vasopressin and copeptin levels showed a significant cor-
relation when blood samples were centrifuged at 2000 g 
and 5000 g (Spearman’s r = 0.84; p = 0.002 and r = 0.89; 
p < 0.001, respectively) but not when blood samples were 
centrifuged at 800 g (Spearman’s r = 0.54; p = 0.11).
Effect of short-term storage
In whole blood stored at 25 °C, an increase in vasopres-
sin concentration of 48% was observed already after 2 h 
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Table 2: Effect of relative centrifugation force (RCF) on platelet count and plasma vasopressin and copeptin levels.
  800 g   2000 g  5000 g  p-Value
Platelet count, × 109/L  263.5   55.5b  3.5b  < 0.001
  [212.3–422.8]   [37.8–70.3]  [2.5–13.3] 
  Reference   – 81%  – 97% 
Vasopressin, pmol/L   4.8   1.5b  0.7b  < 0.001
  [3.3–12.5]   [0.6–2.3]  [0.3–1.2] 
  Reference   – 73%a  – 86%a 
Copeptin, pmol/L   5.5   5.7  5.3  0.74
  [3.2–10.2]   [2.9–10.5]  [3.0–10.2] 
  Reference   – 3%  – 3% 
Absolute values are provided as median and [interquartile range] in pmol/L. Percentages indicate mean percentage change compared to the 
reference value. aExceeding the Acceptable Change Limit (predefined as 25% for vasopressin and 19% for copeptin). bp<0.05 compared to 
the reference value.
of storage, and increased even further during continued 
storage at 25 °C. In whole blood stored at 4 °C, vasopres-
sin was more stable, namely up to 6 h (+ 20%). Copeptin 
concentrations in whole blood were stable at both tem-
peratures for at least 24 h (at 25 °C + 3% and at 4 °C + 1%). 
In plasma, vasopressin concentration remained stable 
up to 6 h when stored at 25 °C (+ 6%) and for at least 24 h 
when stored at 4 °C (– 2%). Again, copeptin concentra-
tion remained stable for all short-term storage conditions 
studied. These data are summarized in Table 3 and in 
Figure 1.
Effect of long-term storage
In Table 4, the effect of pre-measurement storage at 
– 20 °C, – 80 °C and – 150 °C for 1 week, 1 month and 
4 months is shown. Plasma levels measured immediately 
after blood withdrawal and centrifugation at 2000 g were 
used as a reference. Plasma vasopressin levels decreased 
by 26% after 4  months in – 20 °C, exceeding the ACL of 
25%. In contrast, vasopressin was stable for the total 
study duration in samples stored at – 80 °C and – 150 °C. 
Copeptin was stable during the entire study duration at all 
three storage temperatures.
Effect of repeated freezing and thawing
Vasopressin was affected by repeated freezing and 
thawing, as is shown in Figure 2 and Supplemental Data, 
Table 2. After four cycles, change in vasopressin con-
centration exceeded the predefined ACL of 25% with a 
decrease of 32% (from 1.5 [0.6–2.3] to 1.0 [0.3–1.3] pmol/L, 
p < 0.001). Of note, after one freeze-thaw cycle the per-
centage change in measured vasopressin concentration 
already approached the ACL with a decrease of 21% (from 
1.5 [0.6–2.3] to 1.2 [0.4–2.2] pmol/L, p = 0.06). In contrast, 
copeptin concentration was not affected by repeated freez-
ing and thawing with only a non-significant 4% increase 
after four cycles. Large differences in the effect of repeated 
freezing and thawing on plasma vasopressin levels were 
observed between study subjects, with both positive as 
well as negative changes (Supplemental Data, Figure 1), 
indicating that repeated freeze-thawing not only causes 
a systematic decrease, but also an increase in variability 
of measured vasopressin concentration. This was not the 
case for copeptin (Supplemental Data, Figure 1).
Discussion
Our study showed that centrifugation speed, short-term 
storage temperature (pre- as well as post-centrifugation), 
and repeated freezing and thawing had a considerable 
effect on vasopressin levels, but not on copeptin concen-
trations. Long-term storage for 4  months at – 80 °C and 
– 150 °C did not affect plasma vasopressin nor copeptin 
levels, but vasopressin concentration decreased signifi-
cantly when stored at – 20 °C.
Our observation that a decrease in plasma plate-
let count, induced by higher centrifugation speed, was 
accompanied by a decrease in plasma vasopressin con-
centration is in agreement with findings published already 
20 years ago [11, 12]. In one of these studies it was demon-
strated that platelet-rich plasma (centrifuged at 140 g) and 
platelet-free plasma (additional centrifuging at 25,000 g) 
differed considerably regarding vasopressin levels and it 
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Table 3: Effect of short-term storage on plasma vasopressin and copeptin levels.
  Reference 
value
  2 h  6 h  24 h  p-Value
Whole blood
 Vasopressin, pmol/L
  25 °C   1.2   1.3  2.0b  3.1b  < 0.001
  [0.4–2.2]   [1.0–2.2]  [1.0–4.1]  [1.7–8.4] 
  Reference   + 48%a  + 120%a  + 247%a 
  4 °C   1.2   1.1  1.1  1.4  0.20
  [0.4–2.2]   [0.4–3.2]  [0.6–2.5]  [1.0–3.6] 
  Reference   – 7%  + 20%  + 104%a 
 Copeptin, pmol/L
  25 °C   5.2   5.5  5.1  5.7  0.52
  [3.3–10.3]   [2.9–10.3]  [2.8–10.4]  [2.8–10.7] 
  Reference   ± 0%  ± 0%  + 3% 
  4 °C   5.2   4.9  5.7  5.7  0.97
  [3.3–10.3]   [3.0–10.6]  [3.1–9.7]  [3.1–10.1] 
  Reference   ± 0%  + 5%  + 1% 
Plasma
 Vasopressin, pmol/L
  25 °C   1.2   1.2  1.1  1.4b  0.05
  [0.4–2.2]   [0.4–1.8]  [0.5–1.8]  [0.6–2.2] 
  Reference   + 10%  + 6%  + 34%a 
  4 °C   1.2   1.2  1.3  0.9  0.60
  [0.4–2.2]   [0.4–1.9]  [0.4–2.0]  [0.4–2.1] 
  Reference   ± 0%  + 4%  – 2% 
 Copeptin, pmol/L
  25 °C   5.2   5.3  5.6  5.6  0.77
  [3.3–10.3]   [3.3–10.4]  [3.7–10.2]  [3.3–10.5] 
  Reference   – 1%  + 12%  + 11% 
  4 °C   5.2   5.7  5.5  5.4  0.74
  [3.3–10.3]   [3.5–12.8]  [3.4–10.2]  [3.4–9.9] 
  Reference   + 3%  + 7%  + 5% 
Absolute values are provided as median and [interquartile range] in pmol/L. Percentages indicate mean percentage change compared to the 





































0 h 2 h 6 h 24 h
Figure 1: The effect of storage of whole blood and plasma at 4 °C and 25 °C on vasopressin and copeptin concentration.
Data points represent mean percentage change from baseline (reference). The horizontal dotted lines represent the acceptable change 
limits (ACL). Legend:  whole blood stored at 25 °C;  whole blood stored at 4 °C;  plasma stored at 25 °C;  plasma stored at 
4 °C.
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was concluded that ~ 90% of circulating vasopressin was 
bound to platelets via V1 receptor binding [12, 22]. To our 
knowledge, our study is the first to show that copeptin 
concentration, in contrast to vasopressin concentration, 
is not influenced by centrifugation speed, which sug-
gests that copeptin is not platelet-bound. The correlations 
between vasopressin and copeptin were significant when 
centrifuged at 2000 g or 5000 g and differed across the 
various centrifugation speeds, with the strongest correla-
tions being obtained at the highest centrifugation speed. 
We assume that the variation in measured vasopressin 
concentration is greater when a lower centrifugation 
speed is used due to inter-individual differences in plate-
let count, explaining the lower correlation coefficient. Dif-
ferences in centrifugation speed may possibly explain the 
variability of the correlations between vasopressin and 
Table 4: Effect of long-term storage on plasma vasopressin and copeptin levels.
  Reference 
value
  1 week  1 month  4 months  p-Value
Vasopressin, pmol/L
 – 20 °C   1.5   1.1  1.3  1.1b  0.02
  [0.6–2.3]   [0.4–2.0]  [0.5–3.1]  [0.3–2.0] 
  Reference   – 21%  – 9%  – 26%a 
 – 80 °C   1.5   1.2  1.5  1.3  0.05
  [0.6–2.3]   [0.4–2.2]  [0.7–2.3]  [0.6–2.6] 
  Reference   – 21%  + 11%  – 3% 
 150 °C   1.5   1.2  1.3  1.0  0.93
  [0.6–2.3]   [0.5–2.4]  [0.6–3.3]  [0.5–1.7] 
  Reference   – 5%  + 9%  – 2% 
Copeptin, pmol/L
 – 20 °C   5.7   5.5  4.7  5.5  0.43
  [2.9–10.5]  [3.4–10.2]  [3.1–9.2]  [3.3–10.4] 
  Reference   + 4%  – 4%  + 2% 
 – 80 °C   5.7   5.2  6.0b  5.6  0.04
  [2.9–10.5]  [3.3–10.3]  [3.0–10.3]  [3.4–10.5] 
  Reference   ± 0%  + 7%  + 5% 
 – 150 °C  5.7   5.3  5.3  6.0  0.95
  [2.9–10.5]  [3.4–10.6]  [3.4–10.6]  [3.4–12.4] 
  Reference   + 5%  + 6%  + 3% 
Absolute values are provided as median and [interquartile range] in pmol/L. Percentages indicate mean change compared to reference value. 





































0 1 2 4
Figure 2: The effect of repeated freeze-thaw cycles on plasma vasopressin and copeptin concentration.
Data points represent mean percentage change from baseline (reference) ± SD. The shaded areas represent the acceptable change limits 
(ACL). Legend: ◆ reference (100%).
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copeptin that have been published in previous studies, 
ranging from 0.31 to 0.88 [3, 6, 23, 24]. Our results empha-
size both the importance of using a uniform centrifugation 
speed and the need of a clear description of the applied 
centrifugation speed in studies that measure vasopressin 
concentration. Specifically, g-force (RCF), as opposed to 
the rounds per minute (RPM) should be stated, as the RCF 
is independent of the centrifuge diameter.
In addition to centrifugation force, short-term storage 
temperature and time before processing blood samples 
affected vasopressin concentration. Vasopressin was 
found to be less stable in whole blood than in plasma. 
Also, storage temperature of 25 °C led to less stability of 
vasopressin in both whole blood and plasma compared to 
4 °C. We observed that vasopressin concentration in whole 
blood increased significantly over time, both at room tem-
perature (25 °C) and 4 °C. This may be explained by the 
fact that in plasma after centrifugation free vasopressin is 
measured, not platelet-bound vasopressin, and that vaso-
pressin is released from platelets during storage, leading 
to an increase in measured concentration. Two previous 
studies also showed an increase in vasopressin levels 
when whole blood was stored at 25 °C with greater stability 
when blood samples were stored at 4 °C [11, 13]. However, 
in these studies vasopressin in whole blood stored at 4 °C 
had longer stability than in our study; at least 24 [13] and 
even up to 48 h [11] compared to 6 h, respectively. These 
differences may be explained by the lack of power of the 
statistical tests implemented in these studies, due to an 
insufficient number of participants. The stability of vas-
opressin in plasma observed in our study is in line with 
the literature [9, 12]. Although we did not specifically 
study the effect of blood sample collection on ice and 
centrifuge temperature it can be expected, based on our 
results of short-term storage temperature of whole blood, 
that vasopressin levels are more stable when samples are 
collected on ice and centrifuged at 4 °C in comparison to 
25 °C, which is in line with the literature [12]. In contrast, 
copeptin was not affected by storage temperature condi-
tions in our as well as in other studies [3, 14]. These results 
indicate that for copeptin measurement it is not necessary 
to collect blood samples on ice or to centrifuge tubes in a 
chilled environment.
The present study is the first to show that both vaso-
pressin and copeptin are stable in plasma when stored 
frozen at – 80 °C and – 150 °C for at least 4 months. When 
stored at – 20 °C, plasma vasopressin remained stable 
for only 1 month, whereas copeptin was stable for at least 
4 months. Our finding with respect to vasopressin stability 
at – 20 °C is in contrast with findings in a previous study 
that showed that vasopressin is not stable when stored for 
24 h [17]. This study was, however, performed in the 1970s 
and discrepancies might be a caused by differences in the 
vasopressin assay that was used, which has improved 
significantly over the years [11], or by blood collection in 
lithium heparin instead of EDTA collection tubes [9].
We observed that vasopressin was affected by repeated 
freezing and thawing, whereas no effect on copeptin 
levels was found up to four freeze-thaw cycles. A trend 
for a decrease in vasopressin concentration was observed 
after already one freeze-thaw cycle. Moreover, we found 
that the extent of the effect of freezing and thawing on the 
vasopressin concentrations varied across samples that 
were studied, indicating that repeated freeze-thaw cycles 
induce beside a systematic decrease also more variability, 
both of which are undesirable. Literature on the effect of 
freezing and thawing is scarce. To our knowledge, only 
one study reported that endogenous vasopressin level 
did not change after three subsequent freeze-thaw cycles 
[17]. However, this has only been studied in one sample. 
Likewise, only one study investigated the effect of freezing 
and thawing on copeptin levels and found no effect of four 
freeze-thaw cycles [3], in agreement with our findings.
We acknowledge that this study has limitations. In this 
study we only examined stability during a frozen storage 
up to 4 months. Future studies should address the stabil-
ity of vasopressin and copeptin stored for longer periods 
of time. In addition, vasopressin and copeptin levels were 
measured only once in each specific condition, which 
may have increased the chance of unjustly accepting the 
analytes to be (un)stable. However, performing multi-
ple measurements would have required an unfeasible 
amount of blood samples and volume per individual. By 
using the ACL to conclude whether changes are relevant, 
we corrected for potential measurement errors, because 
when values exceed the ACL this provides 95% certainty 
that a change in analyte concentration is not due to assay 
variability. The implementation of the ACL as a measure 
for stability, as opposed to merely statistical analysis, is a 
significant strength of this study. Another strength is that 
our study is the first to compare the effect of several pre-
analytic sample handling conditions on vasopressin and 
copeptin within the same study. In addition, this study is 
an investigator-initiated study and was performed inde-
pendently of the manufactures of the copeptin and vaso-
pressin assays.
Based on our study results pre-analytical sample han-
dling recommendations can be made. For measurement of 
vasopressin, blood samples should be collected on ice and 
centrifuged at 4 °C immediately after collection at preferably 
2000 g or higher RCF. Short-term storage of plasma samples 
is preferred at 4 °C for a maximum time span of 24 h or, if 
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storage for a longer period is inevitable, plasma samples 
should be stored at – 80 °C. Repeated freeze-thaw cycles 
should be avoided. For measurement of copeptin, a less 
stringent pre-analytical sample handling protocol is neces-
sary as copeptin remained stable in all study conditions.
Conclusions
This study provides more insight in the ex vivo stability 
of vasopressin and copeptin and adds to the knowledge 
on optimal sample handling in order to perform reliable 
measurements. In view of our results, we recommend the 
use of a strict sample handling protocol in measurements 
of vasopressin, both to improve between study compari-
son of vasopressin levels so as to ensure within-laboratory 
consistency. In contrast, a less strict protocol for copeptin 
is required, making measurement of copeptin as surrogate 
for vasopressin an attractive alternative.
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